The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Nov. 07, 2018
Applicant:

Queen's University AT Kingston, Kingston, CA;

Inventors:

Sara Mohajeri, Milton, CA;

Brian G. Amsden, Kingston, CA;

Fei Chen, Kingston, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/34 (2017.01); A61K 31/573 (2006.01); A61L 31/16 (2006.01); A61L 31/14 (2006.01); A61L 31/10 (2006.01); A61L 31/06 (2006.01); A61K 9/00 (2006.01); C08G 64/16 (2006.01); A61L 29/14 (2006.01); A61L 29/16 (2006.01); A61L 29/08 (2006.01); A61L 27/58 (2006.01); A61K 9/08 (2006.01); A61L 27/54 (2006.01); C08G 64/30 (2006.01); A61L 27/34 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/0029 (2013.01); A61K 9/08 (2013.01); A61K 31/573 (2013.01); A61L 27/34 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); A61L 29/085 (2013.01); A61L 29/148 (2013.01); A61L 29/16 (2013.01); A61L 31/06 (2013.01); A61L 31/10 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); C08G 64/1608 (2013.01); C08G 64/305 (2013.01); A61L 2300/252 (2013.01); A61L 2300/256 (2013.01); A61L 2300/258 (2013.01); A61L 2300/416 (2013.01); A61L 2300/43 (2013.01); A61L 2300/606 (2013.01); A61L 2400/06 (2013.01); A61L 2420/00 (2013.01);
Abstract

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.


Find Patent Forward Citations

Loading…